Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ATTENUATION - A Multicenter Randomized Phase II Study of the Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma (PRODIGE99/FRENCH 39 Study)

NCT06933966 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT06933966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06933966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ATTENUATION - A Multicenter Randomized Phase II Study of the Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma (PRODIGE99/FRENCH 39 Study)
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
September 1, 2032
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma or gastroesophageal junction adenocarcinoma or esophageal carcinoma, non metastatic disease